ClinVar Miner

Submissions for variant NM_144573.4(NEXN):c.1981G>A (p.Gly661Arg)

gnomAD frequency: 0.00001  dbSNP: rs876657929
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000222628 SCV000272213 uncertain significance not specified 2015-04-10 criteria provided, single submitter clinical testing The p.Gly661Arg variant in NEXN has not been previously reported in individuals with cardiomyopathy or in large population studies. Computational prediction too ls and conservation analysis suggest that this variant may impact the protein, t hough this information is not predictive enough to determine pathogenicity. In s ummary, the clinical significance of the p.Gly661Arg variant is uncertain.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV000768811 SCV000900184 uncertain significance Cardiomyopathy 2016-11-24 criteria provided, single submitter clinical testing
Invitae RCV001359679 SCV001555557 uncertain significance Dilated cardiomyopathy 1CC; Hypertrophic cardiomyopathy 20 2020-07-01 criteria provided, single submitter clinical testing This sequence change replaces glycine with arginine at codon 661 of the NEXN protein (p.Gly661Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with NEXN-related conditions. ClinVar contains an entry for this variant (Variation ID: 229056). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002415903 SCV002718327 uncertain significance Cardiovascular phenotype 2021-10-11 criteria provided, single submitter clinical testing The p.G661R variant (also known as c.1981G>A), located in coding exon 12 of the NEXN gene, results from a G to A substitution at nucleotide position 1981. The glycine at codon 661 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000222628 SCV004122034 uncertain significance not specified 2023-10-23 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.